Oncosalud Sac

Lima Lima 41

1 studies enrolling now · 7 studies all time

What they study most

Breast Cancer, Breast Screening, Colorectal Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, Neoplasms, Colorectal, Non-Hodgkin Lymphoma

Studies at this site

• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now
• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma — Running, not enrolling
• Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) — Running, not enrolling
• Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy — Completed